1 Myelomeningocele (MMC) is a congenital disease without genetic abnormalities. 2 Neurological symptoms are irreversibly impaired after birth. No effective treatment has 3
Introduction 1
Myelomeningocele (MMC) is the most common neural tube defect characterized by a 2 skin defect in addition to defects of the midline vertebra and dura mater. Under these 3 conditions, the spinal cord is exposed to the external environment. Although MMC is 4 compatible with survival, this condition ranks as one of the most severe birth defects, 5 with the manifestation of sequelae that affect both the central and peripheral nervous 6 systems, leading to lifelong paralysis and dysfunction of the bladder and bowel for 7 which no cures exist. The two-hit hypothesis postulates irreversible neurological deficits 8 during pregnancy. First, a failure of primary neurulation results in the neural tube defect. 9
Second, the subsequent destruction of the exposed neural tissue is attributed to the 10 chemical damage by amniotic fluid (AF) containing meconium and to the physical 11 damage caused by the direct trauma (Heffez et al., 1990; McLone and Knepper, 1989; 12 Michejda, 1984) . Therefore, fetal intervention is focused to prevent progressive 13 neurological damage in utero (Bruner et al., 2004; Johnson et al., 2003; Sutton et al., 14 1999; Tubbs et al., 2003; Tulipan et al., 1999; Tulipan et al., 2003; Walsh et al., 2001) . 15
The first human randomized-controlled clinical trial entitled the "Management of 16
Myelomeningocele Study (MOMS)" has found that intrauterine repair of fetal MMC 17 improves the neurological prognosis compared with postnatal MMC repair (Adzick et 18 al., 2011) . However, the MOMS trial also proved that severe complications such as 19 preterm birth, premature rupture of the membrane, and placental abruption and uterine 20 wall dehiscence at the repair site increased due to a large incision of the uterine wall. 21 Moreover, the skin defect is too large to allow skin closure in 20%-30% of fetuses with 22 MMC (Mangels et al., 2000) . Although several less invasive methods that prevent 23 leaking of cerebral spinal fluid with coverage of the exposed spinal cord using various 24 coverage materials, such as gelatin sponge incorporating basic fibroblast growth factor 25 and autologous amniotic membrane, have been reported, improvement of neurological 26 function remains insufficient because insufficient recovery of neural damage occurs 27 during pretreatment (Brown et al., 2014; Kohl et al., 2006; Kohl et al., 2009; Watanabe 28 et al., 2010; Watanabe et al., 2011) . Thus, the development of a less invasive method is 29 required to be applied during earlier gestation. 30 31 Coverage of a skin defect by a three-dimensional (3D) skin enables fetal intervention to 32 be not only less invasive but also completed by an earlier term of pregnancy because 1 autologous cultured skin transplantation enhance wound healing such as autologous 2 skin transplantation for patients with severe burns (Pham et al., 2007) . Moreover, 3D 3 skin may grow in harmony with the fetal growth during all pregnancy periods. However, 4 it is difficult to provide available autologous skin grafts for a fetus with MMC. 5 Furthermore, the strong demand far outstrips the current supply of skin graft. Therefore, 6
we hypothesize that induced pluripotent stem cells (iPSCs) can be an ideal new material 7 for autologous skin transplantation. The first clinical therapy using human iPSCs treated 8 a Japanese woman with macular degeneration (Sivan et al., 2016) . A great deal of 9 research is currently in progress to facilitate therapy for patients with intractable 10 diseases, such as Parkinson' disease and spinal cord injury (Cherry and Daley, 2012, 11 2013) . iPSCs can provide therapeutic potential for tissue repair and regeneration in 12 combination with in vitro differentiation. The use of iPSCs in clinical application has 13 largely been welcomed by society because the use of these cells avoids the substantial 14 ethical concerns and immune rejection. 15
16
In the present study, we generated human iPSCs from amniotic fluid cells (AFCs) using 17 feeder-free, xeno-free, and integration-free systems. To verify that iPSCs could be 18 generated from fetuses with severe fetal disease, we chose two major fetal diseases, 19 twin-twin transfusion syndrome (TTTS) and trisomy 21 (T21): TTTS is one of the most 20 serious complications of monochorionic multiple gestations; fetal intervention is most 21 frequently performed, and trisomy 21 is the most common chromosome abnormality 22 among liveborn infants. To apply iPSC-based cell therapy during earlier gestational age, 23
we established an effective protocol for differentiation of iPSCs into keratinocytes by 24 the addition of Y-27632 and epidermal growth factor (EGF). We successfully 25 established a novel surgical approach in the fetal rat model of MMC using reconstructed 26 3D skin with iPSC-derived keratinocytes (iPSC-KC) and investigated the effect of 27 transplantation of 3D skin. 28 29
Materials and Methods 30

Ethical statement 31
The protocol for the use of human cells in the present study was approved by the 32 Institutional Review Board of the National Research Institute for Child Health and 1 Development of Japan and was in full compliance with the Ethical Guidelines for 2
Clinical Studies (Ministry of Health, Labor, and Welfare). 3 4 Human cells 5 AF was obtained from fetus with Down syndrome and TTTS, with both conditions 6 associated with polyhydramnion. In case of TTTS, AF was obtained at the time of 7 fetoscopic laser surgery at gestational ages ranging from the 19th to 26th weeks. In the 8 cases of Down syndrome, AF was obtained by amnioreduction at 29 weeks of gestation. 9 Cells were obtained by the centrifugation of 20-ml AF at 1,500 rpm for 10 min after 10 filtration through a 100-μm filter. The supernatant was removed, and the precipitates 11 were seeded in 60-mm tissue culture dishes, which were precoated with 0.1% gelatin. 12
These cells were incubated at 37°C under 5% humidified CO 2 in 4 ml of 13
AmnioMAX TM -II Complete Medium (Invitrogen, cat. no. 11269-016) . Cell clusters 14 were emerged at 6-7 days after seeding. Nonadherent cells were discarded, and the 15 media was changed every 2 days. When the cultures reached subconfluence, the cells 16 were harvested with a trypsin-ethylenediaminetetraacetic acid (EDTA) solution (Wako, 17 cat. no. 209-16941) and replated at a ratio 1:8 in a 60-mm dish. These cells were 18 cultured and passaged routinely at 70%-80% confluence. The cells at passages 3-4 19 were used for the generation of iPSCs. 20 21 HDK1-K4DT, an immortalized keratinocyte, was grown in a keratinocyte serum-free 22 medium (KSFM) (Invitrogen, cat. no. 17005-042) and supplemented with 10 μ M 23 Y-27632 (Wako, cat. no. 251-00514) (Egawa et al., 2012) . Subconfluent cultures of 24 HDK1-K4DT were passaged at a ratio 1:6. HDK1-K4DT at less than passage 20 was 25 used for organotypic culture. HFF2, an immortalized fibroblast, was grown in 26 Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine 27 serum (FBS) (Tatsumi et al., 2006) . 28
29
Generation of feeder-free iPSCs 30 AF-derived cells (AFCs) were seeded at 6 × 10 5 /well in a six-well plate and maintained 31 RNA was extracted from cells using the RNeasy Plus Micro kit (Qiagen, cat. no. 74004) . 23
An aliquot of total RNA was reverse transcribed using an oligo (dT) primer (Invitrogen, 24 cat. no. 18418-20) . For the thermal cycle reactions, the cDNA template was amplified 25 (Applied Biosystems ® Quantstudio TM 12K Flex Real-Time PCR System) with 26 gene-specific primer sets using the Platinum Quantitative PCR SuperMix-UDG with 27 ROX (Invitrogen, cat. no. 11743-100) under the following reaction conditions: 40 28 cycles of PCR (95°C for 15 s and 60°C for 1 min) after an initial denaturation (95°C for 29 2 min). Fluorescence was monitored during every PCR cycle at the annealing step. The 30 authenticity and size of the PCR products were confirmed using a melting curve 31 analysis (using software provided by Applied Biosystems). mRNA levels were 32 normalized using glyceraldehyde-3-phosphate dehydrogenase as a housekeeping gene. 1 2
Immunocytochemical analysis 3
Cells were fixed with 4% paraformaldehyde (PFA) in PBS for 10 min at 4°C. After 4 washing with PBS and treatment with 0.1% Triton X-100 (Sigma-Aldrich, cat. no. 5 T8787-100ML) for 10 min at 4°C, cells were pre-incubated with 5% normal goat serum 6 (Dako, cat. no. X0907) in PBS for 30 min at room temperature, following which they 7 were reacted with primary antibodies in blocking buffer for 24 h at 4°C. After washing 8 with PBS, cells were incubated with fluorescently coupled secondary antibodies; 9 anti-rabbit or anti-mouse IgG conjugated with Alexa 488 or 546 (1:1000) in blocking 10 buffer for 30 min at room temperature. The nuclei were stained with 11 4′,6-diamidino-2-phenylindole (DAPI) (Biotium, cat. no. 40043) . All images were 12 captured using confocal microscopy (LSM 510 and LSM 510 META laser scanning 13 microscope). Antibody information is provided in Supplemental Table S2 . 14 15
Karyotypic analysis 16
Karyotypic analysis was performed at the Nihon Gene Research Laboratories Inc. 17 (Sendai, Japan). Metaphase spreads were prepared from cells with 100 ng/ml of 18 Colcemid (Karyo Max, Gibco Co. BRL) treatment for 6 h. The cells were fixed with 19 methanol:glacial acetic acid (2:5) three times and dropped onto glass slides (Nihon 20 Gene Research Laboratories Inc.). Chromosome spreads were Giemsa banded and 21 photographed. Twenty metaphase spreads were analyzed for each sample and 22 karyotyped using a chromosome imaging analyzer system (Applied Spectral Imaging, 23 Carlsbad, CA). 24 25 Short tandem repeat analysis 26 Short tandem repeat analysis was performed at BEX CO., LTD. Using the genomic 27 DNA extracted from iPSCs generated from patients with TTTS (AF-TTTS-iPSCs) and 28 TTTS (AF-TTTS-iPSCs), 16 microsatelite markers were amplified by PCR with 29 microsatellite-specific primers. 30 31 Whole-exome sequencing 1 Approximately 2.0 µg of genomic DNA from each cell sample was sonicated to provide 2 an average fragment size of 200-300 bp on a Covaris S220 instrument. After 5 cycles of 3 PCR amplification, capture and library preparation were performed with Agilent 4 SureSelect Human All Exon V5 + lincRNA (50 Mb), followed by washing, elution, and 5 additional 12-cycle PCR amplification to attach index adaptors. Enriched libraries were 6 sequenced on an Illumina HiSeq 2500 operated in 100-bp paired-end mode. Image 7 analyses and base calling on all lanes of data were performed using bcl2fastq 1.8.4 with 8 default parameters. 9 10
Read mapping and variant analysis 11
Reads from the sample were first trimmed by removing adapters using cutadapt 1.7.1 12 and low-quality bases at ends using a custom script. Then, they were aligned to the 13 hs37d5 sequence (hg19 and decoy sequences) using the Burrows-Wheeler Aligner 14 0.7.10. Mapped reads were converted from SAM to BAM using SAMtools 1.2 and 15 processed by Picard 1.109 to eliminate PCR duplicate reads. The Genome Analysis 16 Toolkit (GATK) 3.4 was then used to perform local realignment with known indel sites 17 and map quality score recalibration to produce calibrated BAM files. Multi-sample 18 callings for single-nucleotide variants (SNVs) were made by GATK. The annotated 19 variant call format files were then filtered using GATK with a stringent filter setting and 20 custom scripts. Annotations of detected variants were made using ANNOVAR based on 21
GRCh37. Genotypes of control samples were shuffled for each variant from a 22 perspective of protection of personal information. 23 24 Teratoma formation 25 iPSCs were harvested by accutase treatment, collected into tubes, and centrifuged. The 26 same volume of basement membrane matrix (BD Biosciences, cat. no. 354234) was 27 added to the cell suspension. The cells (>1 × 10 7 ) were subcutaneously inoculated into 28 immunodeficient nude mice (BALB/cAJcl-nu/nu) (CREA, Tokyo, Japan). After 29 6-8 weeks, the resulting tumors were dissected and fixed with PBS containing 4% PFA. 30
Paraffin-embedded tissue was sliced and stained with hematoxylin and eosin. The 31 operation protocols were accepted by the Laboratory Animal Care and the Use 1 Committee (A2003-002-C13-M05). 2 3 Fluorescence-activated cell sorting analysis 4
The expression of cell surface markers on AFCs cultured in the amniomax II at passage 5 3 and keratinocytes derived from iPSCs were analyzed by flow cytometry. The AFCs 6 and iPSC-derived keratinocytes were harvested by Trypsin-EDTA solution treatment 7 and fixed with 2% PFA/PBS for 15 min at RT. After PBS wash, cells were permeabilized 8 with 0.1% saponin (Wako, and blocked with 5% goat serum. Primary 9 antibodies were incubated for 1 h in PBS with 1% bovine serum albumin. After washing 10 with PBS, cells were incubated with fluorescently coupled secondary antibodies; 11 anti-rabbit or anti-mouse IgG conjugated with Alexa 488 (1:1000) for 30 min at room 12 temperature. Secondary stain cells were analyzed on a BD LSR Fortessa (BD 13 Biosciences 20 ng/ml EGF. iPSC-derived keratinocytes were seeded at 3 × 10 4 /cm 2 cells and 30 enriched by rapid adherence to fibronectin and type I collagen-coated dishes for 31 15-30 min at room temperature. Nonadherent cells were discarded, and rapidly attached 1 cells were cultured. EB method (protocol C) was performed as described previously 2 (Bilousova et al., 2011) . Embryonic bodies (EBs, n=100) were formed from 5 × 10 4 3 iPSCs on a Petri dish in embryonic stem cell medium without basic fibroblast growth 4 factor (ESC-no-bFGF medium). After 2 days, 30 EBs were transferred to a new Petri 5 dish with ESC-no-bFGF medium containing 1-μM RA for three days in suspension 6 culture. EBs were then transferred onto a type-IV (Sigma-Aldrich, cat. no. 7 C7521-10MG)-coated 100-mm dish with ESC-no-bFGF medium containing 25-ngml -1 8 BMP4. After 3 days, the medium was switched to DKSFM, and the plated EBs were 9 cultured for six days. EB remnants were removed by vacuum aspiration, and 10 iPSC-derived keratinocytes were subcultured onto type-IV-coated 100-mm dish and 11 selected rapid attachment to type-IV-coated dish for 15 minutes at room temperature in 12 DKSFM. 13 14 Generation of 3D skin equivalent 15 3D skin was generated according to a previously described protocol (Tsunenaga et al., 16 1994) . To prepare the dermal equivalent, type I collagen (Koken Co., cat. no. IPC-50) 17 and DMEM plus 10% FBS containing 1 × 10 6 HFF2s were mixed and poured into an 18 untreated 60-mm Petri dish while cooling and allowed to gel at 37°C for 1 h. 19
Contraction of the collagen gel was facilitated by pulling the gel from the surface of the 20 Petri dish. The medium was changed every 2 or 3 d for 7 d. HDK1-K4DT or 21 iPSC-derived keratinocytes were plated at 2 × 10 5 or 1 × 10 6 cells inside in a glass ring 22 (10 mm diameter) on the surface of the contracted collagen gel, which was plated onto 23 polyethylene terephthalete membranes (Corning, . iPSC-derived 24 keratinocytes were grown in DKSFM supplemented with 10 μ M Y-27632 and 20 ng/ml 25 EGF for 2 days, following which they were exposed to air in a 1:1 mixture of KSFM 26 and DMEM plus 10% FBS, in which the Ca 2+ concentration was adjusted to 1.8 mM. 27
The medium was changed every 2 or 3 days. Multilayered 3D cultures of keratinocytes 28 were obtained by days 14-21. 29 30 Animal preparation and RA exposure 1
The procedure for creating MMC defects in fetal rats was based on the protocol 2 described earlier (Danzer et al., 2005; Watanabe et al., 2010) . Briefly, time-dated 3 Sprague-Dawley rats (CLEA Japan, Tokyo or Sankyo Labo Service Co, Tokyo) were 4 used. After being exposed to isoflurane (Wako, cat. no. 099-065-71), anesthetized rats 5 were fed 60 mg/kg all-trans RA (Wako, Tokyo, cat. no. 182-01111) dissolved in olive 6 oil (10 mg/ml) at embryonic day 10 (E10). 7 8 Surgical procedure 9
Fetal intervention of RA-exposed Sprague-Dawley rats was performed at E20. Pregnant 10 rats were anesthetized by isoflurane, and an abdominal midline incision was made to 11 expose the uterine horns. The MMC defect was confirmed through the uterus under 12 direct vision, and a small incision of the uterine wall and amniotic membranes was 13 made directly above the defected site. 3D skin was transplanted into the area of defected 14 skin. Beriplast P Combi-Set (CSL Behring, cat. no. 87799) was used for tissue adhesion. 15
The hysterectomy site was closed by purse-string suture with 6-0 silk (Natsume 16 Seisakusho, cat. no B10-60). The uterus was returned to the abdomen, and the 17 abdominal incision site was closed by running suture. The fetuses were harvested by 18 cesarean section at E22. Pregnant rats were then euthanized by cervical dislocation 19 under anesthesia with isoflurane. The transplantation site was dissected and processed 20 for histological and immunohistochemistry analysis. The primary antibody list is 21 provided in Supplemental Table S2 . Appropriate Alexia488 or alexa594-conjugated 22 secondary antibody was used with DAPI nuclear counterstain. The operation protocols 23 were accepted by the Laboratory Animal Care and the Use Committee 24 (A2015-003-C01). 25 26
Statistical analysis 27
Each experiment was repeated at least three times, and the data are presented as the 28 mean ± SD of the mean. Statistical significance was determined by the student's t test. 29 p < 0.05 was considered statistically significant. 30
31
Results 1
Derivation and characterization of AFCs in patients with polyhydramnion 2
To examine whether iPSCs could be efficiently generated from human AFCs derived 3 from patients with the serious disease coexisting polyhydramnion, we focused on two 4 fetal diseases, namely TTTS and Down syndrome. Human AFCs were isolated from 5 patients with TTTS (TTTS-AFC) and Down syndrome (T21-AFC) with the consents of 6 subjects and the Ethical Review Board of the National Research Institute for Child 7
Health and Development. AF was obtained through amniocentesis under sterile 8 conditions during amnioreduction for therapy of polyhydramnion. Approximately 20 ml 9 of AF is sufficient to obtain AFCs. The average number of viable cells was 10 0.356 × 10 6 /ml ± 0.227 × 10 6 /ml (mean ± standard deviation [SD]). The AFCs showed 11 heterogeneous morphologies and reached confluence by 10 days after cell seeding 12 ( Figure 1A ). Flow cytometry at passage 3 revealed that CD29, CD44, CD73, and 13 human leukocyte antigen (HLA)-ABC [major histocompatibility complex (MHC) 14
class I], were strongly positive; CD117 was rarely positive (0.8%), whereas CD14, 15 CD19, CD34, HLA-DR, DP, and DQ (MHC class II) were negative ( Figure 1B) . 16
Quantitative real-time polymerase chain reaction (qRT-PCR) analysis revealed trace 17 amounts of OCT3/4, NANOG, and SOX2, compared with endometrial-derived 18 mesenchymal stem cells (EDOM-MSCs) ( Figure 1C ). These results indicate that AFCs 19 derived from polyhydramnion have a similar population to a normal volume of AF (De 20 Coppi et al., 2007; Li et al., 2009; Tsai et al., 2004; You et al., 2008) . 21 22
Generation of human iPSCs from AFCs of patients with TTTS and Down syndrome 23
AFCs at passages 3-4 were transfected with episomal vectors carrying six 24 reprogramming factors (L-MYC, KLF4, OCT4, SOX2, LIN28, and short-hairpin RNA 25 for P53) by electroporation. After electroporation, AFCs were subcultured into 26 VTN-coated plates in chemically defined and serum-free Essential 8 medium. We 27 observed the appearance of human embryonic stem cell (hESC)-like colonies 28 30-50 days after electroporation. Colonies with human ESC-like morphology expanded 29 and grew as flat colonies with large nucleo-cytoplasmic ratios with a high level of 30 alkaline phosphatase activity (Figure 2A ). No significant differences in proliferation 31 rates were detected between AF-T21-iPSCs and AF-TTTS-iPSCs. Neither cessation of 1 cell proliferation such as senescence nor apoptosis/cell death was detected during 2 cultivation through 70 passages. The reprogramming efficiency was 0.1% and 0.3% in 3 AF-TTTS-iPSCs and AF-T21-iPSCs, respectively. 4 5
Characterization of AF-T21-iPSCs and AF-TTTS-iPSCs 6
Both AF-TTTS-iPSCs and AF-T21-iPSCs expressed multiple pluripotency markers, 7
including nuclear transcription factors OCT3/4, NANOG, SOX2, as well as surface 8 antigen stage-specific embryonic antigen 4 (SSEA-4) and tumor-related antigen 9 (TRA)-1-60 and TRA-1-81 ( Figure 2B ). qRT-PCR analysis showed that endogenous 10 pluripotency marker genes, including OCT3/4, SOX2, NANOG, telomerase reverse 11 transcriptase (TERT), and DNA methyltransferase 3 beta (DNMT3B), were activated in 12 human iPSCs to a similar extent of those in control hESCs (SEES2) ( Figure 2C ), and 13 the transgenes were fully silenced in AF-T21-iPSCs and AF-TTTS-iPSCs. We next 14 examined the ability for in vitro differentiation by examining the expression of germ 15 layer-specific markers in the embryonic body formation. Our analysis demonstrated that 16 AF-T21-iPSCs and AF-TTTS-iPSCs were capable of differentiating into all three germ 17 layers in vitro ( Figure 2D ). To examine pluripotency of iPSC clones, teratoma formation 18 was performed by implantation of AF-T21-iPSCs and AF-TTTS-iPSCs at the 19 subcutaneous tissue of immunodeficient nude mice. Three independent AF-T21-iPSCs 20 and AF-TTTS-iPSCs clones induced teratomas within 6-8 weeks after implantation. 21
Histological analysis of paraffin-embedded sections demonstrated that all three primary 22 germ layers were generated as shown in Figure 2E . Thus, all AF-T21-iPSCs and 23 AF-TTTS-iPSCs clones examined had potential for multilineage differentiation in vivo. 24
Although teratoma derived from AF-T21-iPSCs showed the presence of 25 neuroblastoma-like tissue (Supplemental Figure S1A ) and liver tissue with a vacuolar 26 structure (Supplemental Figure S1B ), Down syndrome-specific findings were not 27 detected. Karyotypic analyses revealed that the AF-TTTS-iPSCs clones had normal 28 karyotypes ( Figure 2F ), whereas the AF-T21-iPSCs clones had trisomy 21 ( Figure 2G ). 29
Analysis of 16 patterns of the short tandem repeat (STR) site revealed that all STR sites of 30 AF-TTTS-iPSCs and AF-T21-iPSCs matched to those of their parental TTTS-AFC and 31 T21-AFC (Supplemental Figure S1C) . 32 1
Whole-exome analysis of T21-iPSCs 2
The whole-exome analysis, wherein our sample was compared with the GRCh37 3 reference sequence, detected a heterozygous single-nucleotide variant (SNV) in the 4 CRELD1 focus. The C-to-G substitution (rs2302787), which results in a Pro-to-Arg 5 alteration, was situated in exon 4. Several mutations of CRELD1 have been reported to 6 contribute to occurrence of cardiac atrioventricular septal defects in Down syndrome 7 (Maslen et al., 2006) . To know whether the alteration is deleterious, SIFT and 8
Polyphen2 were employed. The former makes influence from similarity of amino acid 9 sequences and gives scores close to zero when a variant is damaging, whereas the latter 10 predicts effects of not only sequences but also 3D structures and provides scores close 11 to 1.0 when a variant is intolerant. The scores for the variants were 0 and 0.999, 12
respectively, suggesting a notable variant. Although its global allele frequency was 13 1.0%, higher frequency of 4.5% was documented for the Japanese population in the 14 1000 Genomes project ( Supplemental Table S3 ). 15 16
Generation and characteristics of iPSC-derived keratinocytes 17
We first attempted to generate iPSC-derived keratinocytes (iPSC-KC) based on the 18 prior differentiation protocol (Bilousova et al., 2011; Guenou et al., 2009; Itoh et al., 19 2011; Metallo et al., 2008; Veraitch et al., 2013) using RA to promote ectodermal fate 20 and BMP4 to block neural fate. To define the effective differentiation protocol, we 21 compared differentiation efficiencies among three different protocols including direct 22 differentiation using VTN-coated dish (protocol A), CytoGraph-coated dish 23 (protocol B), and embryoid body method (protocol C) ( Figure 3A) . Protocols A and B 24 were differed in coating agent. In protocol A, we modified the previously reported 25 protocol (Itoh et al., 2011) by replacing matrigel with a human recombinant protein 26 using VTN. 27 During direct differentiation (protocols A and B), cell senescence was observed at 28 day 30, and these cells could not proliferate after the first passage. The number of 29 keratinocyte-like cells decreased after 17 days and β -galactosidase staining revealed that 30 cellular senescence was observed over 17 days, resulting in an exacerbated cellular state 31 ( Figure 3B ). Therefore, the first passage was performed at 14-17 days in protocols A 32 and B, respectively. 1 2
Effect of Y-27632 on iPSC-KCs 3
Although we detected keratinocyte-like cells during passage 1 of protocols A, B, and C, 4 we examined additional factors to obtain a sufficient number of iPSC-KC and found 5 that Y-27632 was critical. Y-27632 is an inhibitor of Rho kinase that increases the 6 long-term proliferative capacity of primary keratinocytes and promotes the 7 differentiation of human bone marrow MSCs into keratinocyte-like cells (Chapman et 8 al., 2010; Chapman et al., 2014; Li et al., 2015; Suprynowicz et al., 2012) . 9
Keratinocytes derived from iPSCs grown in the presence of Y27632 showed improved 10 cell growth. The comparison of immunostaining of Keratin 14 (KRT14) at passage 2 11 with protocols A, B, and C revealed that the percentage of KRT14-positive cells 12 reached 48.08%, 39.24%, and 23.62% in protocol A, B, and C, respectively, indicating 13 that protocol A is most suitable for iPSC-KC proliferation ( Figure 3C, 3D ). Therefore, 14
during subsequent experiments, differentiation of iPSCs into keratinocytes was 15 performed by protocol A. 16 17
Effect of EGF on iPSC-KCs 18
iPSC-KCs treated with Y-27632 showed improved cell growth; however, cell 19 proliferation remained insufficient, required more than 2 weeks to obtain a sufficient 20 cell number. To promote cell proliferation with a high expression level of epithelial 21 markers, we examined iPSC-KCs to investigate the effect of EGF. iPSC-KCs treated 22 with EGF and Y-27632 for 9 days after first passage (starting cell number was 23 1 × 10 5 /well) showed markedly improved cell growth compared with the cells treated 24 with Y-27632, whereas the cell number of EGF-treated iPSC-KCs without treatment of 25 Y-27632 did not proliferate at all, indicating that the combination of EGF and Y-27632 26 is important for the cell growth of iPSC-KCs ( Figure 3E ). Although iPSC-KCs grown in 27 KSFM showed a higher cell growth than that grown in DKSFM ( Figure 3E ), we used 28 DKSFM for subsequent experiments as it is chemically defined and optimized for 29 growth and expansion of human keratinocytes without the potential contamination 30 derived from animal serum. 31 1 We further analyzed gene expression levels of KRT14 in iPSC-KC at passage 1 and 2 found that iPSC-KCs treated with EGF and Y-27632 expressed KRT14 at a higher level 3 than those treated with Y-27632 alone ( Figure 3F ). Flow cytometric analysis also 4 showed that KRT14-positive population increased in cell number and intensity by 5 addition of Y-27632 and EGF (Supplemental Figure S2A ). Treatment with EGF for day 6 4 to 14 resulted in a marginal yet significantly higher expression of KRT14 ( Figure 3G) . 7 Y-27632 was not included for day 4 to 14 because Y-27632-treated iPSC-KCs before 8 the first passage showed a higher expression of OCT3/4 and NANOG ( Figure 3G ). 9 SSEA4-positive undifferentiated iPSCs were successfully removed by treatment of EGF 10 and Y-27632 after the first passage as confirmed by flow cytometric analysis 11 (Supplemental Figure S2B ). As for the growth medium, DKSFM was used throughout 12 the differentiation process (Supplemental Figure S2C ). Taken together, we concluded 13 that differentiation efficiency of iPSC-KCs was most effective in protocol A using 14 DKSFM supplemented EGF and Y-27632, as shown in Figure 3H . 15 16
Characterization of keratinocytes derived from iPSCs 17
In our protocol, overall induction periods were further reduced compared with 18 previously reported protocols (Guenou et al., 2009; Itoh et al., 2011; Itoh et al., 2013), 19 and iPSC-KCs were successfully increased and could be expanded for greater than five 20 passages at least. Interestingly, in terms of proliferative and differentiation abilities, 21 both Y-27632 and EGF were required for the generation of iPSC-KC. Y-27632 was 22 more of affecting the proliferative ability, and EGF was more of affecting the terminal 23 differentiation. Keratinocytes derived from AF-TTTS-iPSCs (TTTS-iPSC-KCs) and 24 AF-T21-iPSCs (T21-iPSC-KCs) showed keratinocyte-like morphology at passage 4 like 25 HDK1-K4DT ( Figure 4A ). KRT14 gradually increased for each passage ( Figure 4B ). 26
Transcriptional analysis by qRT-PCR showed that the gene expression levels of KRT14, 27 KRT18, p63, OCT3/4, and NANOG of TTTS-iPSC-KCs and T21-iPSC-KCs at 28 passage 4 reached to those in HDK1-K4DT ( Figure 4C ). Interestingly, T21-iPSC-KCs 29 showed higher expression of terminal differentiation markers such as INVOLUCRIN 30
and FILAGGRIN than TTTS-iPSC-KCs ( Figure 4D ). This result is consistent with the 31 clinical features of hyperkeratosis that are frequently observed in patients with Down 32 syndrome. Immunostaining revealed the expression of KRT14, p63, and laminin 5 both 1 in TTTS-iPSC-KCs and in T21-iPSC-KCs ( Figure 4E ). Moreover, keratin 10 (KRT10) 2 and involucrin, markers of differentiated keratinocytes of the suprabasal layer, were 3 induced under a high calcium condition. As expected, the number of involucrin-positive 4 T21-iPSC-KCs increased under a low calcium condition. Keratin 15 (KRT15), a marker 5 of epithelial stem cells in the hair follicle, was rarely detected ( Figure 4E ). The 6 KRT14-positive cell population in EGF and Y-27632-treated iPSC-KC at passage 2 7 reached to 95.9%, as shown by flow cytometric analysis ( Figure 4F ). 8 9 Passage-dependent epidermal differentiation of iPSC-KCs for 3D skin 10 HDK1-K4DT cells had a strong proliferative ability with high expression levels of 11 epithelial markers during the long-term culture period. iPSC-KCs reduced proliferative 12 ability as each passage progressed; however, their terminal differentiation ability 13 increased as each passage progressed ( Figure 4B and Supplemental Figure S3A ). Cell 14 morphology of iPSC-KCs appeared spindle-like during early passages and became 15 similar to human keratinocytes as the passages progressed (Supplemental Figure S3B) . 16
However, a vacuolar degeneration-like structure was observed at passage 5, and the 17 cells ceased to proliferate (Supplemental Figure S3B) . 18
19
For the successful construction of 3D skin with iPSC-KCs, we investigated proper 20 passage number of iPSC-KCs with both sufficient expression levels of KRT14 and the 21 ability of cells to grow. Unfortunately, 3D skin was not generated with iPSC-KCs by 22 the same method as HDK1-K4DT. Thus, we increased the initial seeding cell number of 23 iPSC-KCs from 2 × 10 5 to 1 × 10 6 and allowed 2 d for the culture period in iPSC-KCs 24 before high Ca 2+ induction at the air-liquid interface. iPSC-KCs at passage 0 25 constructed epidermis that were negative for ki67, KRT14, p63 and Pan-cytokeratin 26 (Pan-CK) (Supplemental Figure S4) . The 3D skin with iPSC-KCs at passage 1 revealed 27 immature epithelial-like tissue that expressed pan-CK and Ki67 but not other epithelial 28 markers, including KRT14 and P63 (Supplemental Figure S4) . The 3D skin with 29 iPSC-KCs at later passages (more than passage 4) showed mature keratinocytes with the 30 prickle cell layer that were strongly positive for KRT14, Pan-CK, and involucrin, and 31 weakly positive for Ki67 (Supplemental Figure S4 ). Finally, we successfully identified 32 the most suitable condition to generate a multilayered epidermis with iPSC-KCs at 1 passage 3. The 3D skin with iPSC-KCs at passage 3 after 14 d of air-liquid cultivation 2 had a multilayered epidermis with the KRT14 in the basal compartment and laminin 5 3 at the dermal-epidermal junction ( Figure 5 ). Moreover, KRT10 was detected in the 4 suprabasal layer, and loricrin and filaggrin, late markers of epidermal differentiation, 5
were also observed in the upper layers of the epidermis. These data suggest that 6 AF-TTTS-iPSCs and AF-T21-iPSCs can be differentiated into fully functional 7 keratinocytes for artificial 3D skin. This success may be attributed to the favorable 8 balance of proliferation and differentiation capacities in iPSC-KCs. 9 10 Transplantation of 3D skin into MMC fetal rats 11 A total of 97 fetuses were viable after cesarean section. MMC was present in 83.5% (81 12 of 97) of fetuses exposed to RA. These MMC rats showed a defect in the skin and spine 13 and exposure of the spinal cord ( Figure 6A ). Cross-sectional analysis confirmed the 14 MMC defects and showed the degenerated spinal cord in rats exposed to RA 15 ( Figure 6B ). In total, 20 fetal rats were operated on at day 20 of gestation. The 3D skin 16 with iPSC-KCs was transplanted into fetuses across a small incision of the uterine wall 17 following closure of the incision site ( Figure 6C from direct exposure to the amniotic cavity ( Figure 6D ). Birth weight and crown-rump 23 length (CRL) were significantly lower in the fetal therapy group than in normal rats and 24 non-treated MMC rats ( Figure 6E ). Although the transverse length (TL) and vertical 25 length (VL) of the MMC defect size were slightly shorter in the fetal therapy group than 26 in fetuses without therapy, there were no significant differences when the TL and VL 27 were adjusted for overall fetal CRL ( Figure 6F ). 28 29
Histological evaluation of 3D skin at transplantation site 30
Immunohistochemistry of the transplanted artificial skin with iPSC-KCs and 31 HDK1-K4DT demonstrated that the expression of epithelial markers, such as KRT14 32 and p63 was weak, but obviously remained after birth ( Figure 6G ). Transplanted 3D 1 skin was confirmed using human-specific antigen cytoplasmic protein detected with 2 "stem121". Moreover, epidermal ingrowth was detected at the edge of the epidermis 3 defect in MMC rats, and the epidermis appeared to be elongated underneath the 4 transplantation site (Supplemental Figure S5) . 5 6 Discussion 7
This study is designed to obtain preclinical proof of concept for fetal therapy to patients 8 with MMC using autologous iPSCs. Pregnant women with polyhydramnion need to 9 receive amnioreduction therapy, i.e. 1,000 to 2,000 ml of AF is usually aspirated for 10 preventing threatened premature delivery and respiratory discomfort. A large number of 11
AFCs can be obtained from 20 ml of AF by amnioreduction. The sufficient number of 12
AFCs with their prominent proliferation capability leads to successful iPSC generation 13 from patients with lethal disorders, such as TTTS. 14 15
Artificial Skin with iPSC-epidermal cells and dermal fibroblasts 16
Epidermal sheet products are applied to patients with skin disorders, such as severe burn, 17 giant congenital melanocytic nevus, vitiligo vulgaris, and epidermolysis bulla (Kamao 18 et al., 2014; Kishi et al., 2010; Lu et al., 2014) and are often used with a combination 19 with cryopreserved allogeneic skin, artificial dermis, non-surgical granulation tissue, 20 meshed/patched autologous skin, and fresh allogeneic skin (Matsumura et al., 2016) . 21
Artificial skin with adequate strength is required because not only epidermis but also 22 dermis is absent in the defect site of MMC. Therefore, epidermis alone is not sufficient 23 to cover the defect. 24
25
In addition to the tissue engineering approach with usage of bioengineered products, 26 organoid is formed in vitro in 3D as a miniaturized and simplified version of an organ. 27
The organoid self-organizes in 3D culture through self-renewal and differentiation 28 capacities of pluripotent stem cells, such as iPSCs and ESCs. Organoids, such as eye, 29 gut, liver, and brain, are being developed (Hasegawa et al., 2016; Sasai, 2013; Takebe et 30 al., 2012; Uchida et al., 2016; Yokobori et al., 2016) . A skin organoid, however, has not 31 been developed so far to assure strength to cover the defect site of MMC. 32 1 Challenge of an iPSC therapy to diseased fetus 2
The first autologous cellular therapy was performed to a patient with macular 3 degeneration with iPSCs generated from skin biopsy (Kamao et al., 2014) . Herein, we 4 hypothesize that AFC-derived iPSCs can be used for diseased fetus. The differentiation 5 protocol developed in this study enables earlier induction of keratinocytes from iPSCs 6 than previously reported. However, the window period of acceptable fetal therapy is 7 usually 19-26 weeks of gestation due to fetal condition. Therefore, to perform cellular 8 therapy during pregnancy, allogeneic products with appropriately selected haplotypes 9 may be more feasible because even less than 100 cell lines of iPSCs from banks would 10 be sufficient to cover 90% of the Japanese population (Nakatsuji et al., 2008) . 11 12
Efficient epidermal differentiation of iPSCs with rock inhibitor 13
The efficient keratinocytic differentiation in a short period was achieved by 14 supplementation with both EGF and a rock inhibitor (Guenou et al., 2009; Itoh et al., 15 2011; Itoh et al., 2013) . Y27632, a rock inhibitor, affects the differentiation and 16 proliferation of various types of stem cells (Joo et al., 2012; Kurosawa, 2012; Watanabe 17 et al., 2007) . Moreover, Y27632 enables primary human keratinocytes not only 18 efficiently to bypass senescence but also to increase long-term proliferation (Chapman 19 et al., 2010; Chapman et al., 2014) . Furthermore, Y27632 facilitates differentiation of 20 mesenchymal stem cells into keratinocyte-like cells (Li et al., 2015) . Likewise, 21 Y-27632-treated iPSC-KCs showed improved cell growth and induced differentiation of 22 human iPSCs into functional keratinocytes that were used for manufacturing of 3D skin. 23 24 EGF is the critical factor for the generation of human KRT15-positive epithelial stem 25 cells, which are capable of differentiating into multiple cell types, such as cells of hair 26 follicles and interfollicular epidermis and KRT14-positive basal cells from human 27 iPSCs (Yang et al., 2014) . These are compatible with the results in this study that 28 showed an increased number of KRT14-positive iPSC-KCs and up-regulated expression 29 of the KRT14 gene along with decreased expression of pluripotency markers. In 30 contrast, lack of KRT15 in iPSC-KCs indicates that human iPSC-KCs generated with 31 our protocol comprised a larger proportion of mature keratinocytes than 32 KRT15-positive epithelial stem cells, which may decrease during the induction process. 1
Along with the benefit of EGF, we have to be careful because our differentiation 2 protocol using EGF may induce other types of skin stem cells under certain conditions 3 in 3D culture due to induction of sebocytic lineage with EGF (Zouboulis, 2013). 4 5 Fetal therapy to a patient with MMC with 3D skin 6 Fetal therapy started with patients with TTTS, fetal anemia, and MMC (Adzick and 7 Harrison, 1994; De Lia et al., 1990; Rodeck et al., 1981) ; however, a standard procedure 8
has not yet been developed (Danzer and Johnson, 2014) . As for MMC, laparoscopic 9 surgery to suture skin defects is one of the fetal therapies so far in cases wherein skin 10 defects are not large. Artificial skin needs to be developed due to coverage of large skin 11 defects along with surgical approach. For generation of artificial 3D skin, iPSCs can be 12 efficiently generated from AFCs derived from polyhydramnion in integration-free, 13 xeno-free, and serum-free conditions because AFCs derived from patients with 14 polyhydramnion exhibited prominent proliferative capacity in vitro. In this study, we demonstrated a novel fetal MMC therapy that can be achieved by 30 cellular therapy using AFC-derived iPSCs. Our fetal cell treatment is minimally 31 invasive and therefore has the potential to become a novel treatment for MMC. 32 1 1 This study was supported by a grant from JSPS KAKENHI (grant number 2 JP15K19665). We are grateful to Dr. Tohru Kiyono, Division of virology chief at 3 National cancer center research institute, for donating the cell line of HDK1-K4DT. We 4 sincerely thank Minoru Ichinose (NCDHD) for performing sectioning. The 5 encyclopedic pathological knowledge of Michoyo Nasu (NCDHD) was gratefully 6 appreciated. I am also grateful to the Centre for Maternal-Fetal, Neonatal and 7
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